---
title: "Shanghai Serum Bio-Technology Co., Ltd. (688163.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688163.SH.md"
symbol: "688163.SH"
name: "Shanghai Serum Bio-Technology Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T08:15:05.762Z"
locales:
  - [en](https://longbridge.com/en/quote/688163.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688163.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688163.SH.md)
---

# Shanghai Serum Bio-Technology Co., Ltd. (688163.SH)

## Company Overview

Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.serum-china.com.cn](https://www.serum-china.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.43)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 54 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.77% |  |
| Net Profit YoY | 4.35% |  |
| P/B Ratio | 3.87 |  |
| Dividend Ratio | 0.80% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4314817162.13 |  |
| Revenue | 198029769.23 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.39% | C |
| Profit Margin | 24.58% | A |
| Gross Margin | 72.65% | A |
| Revenue YoY | 1.77% | C |
| Net Profit YoY | 4.35% | C |
| Total Assets YoY | 3.44% | C |
| Net Assets YoY | 1.30% | C |
| Cash Flow Margin | 143.42% | B |
| OCF YoY | 1.77% | C |
| Turnover | 0.17 | D |
| Gearing Ratio | 3.56% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Serum Bio-Technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.77%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "4.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.87",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.80%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4314817162.13",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "198029769.23",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.39%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "24.58%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "72.65%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.77%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "4.35%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.44%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.30%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "143.42%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.77%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "3.56%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 88.63 | 30/81 | 61.55 | 56.99 | 51.72 |
| PB | 3.87 | 51/81 | 2.53 | 2.32 | 2.12 |
| PS (TTM) | 21.79 | 72/81 | 14.32 | 13.21 | 12.02 |
| Dividend Yield | 0.80% | 25/81 | 1.46% | 1.33% | 1.21% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688163.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688163.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688163.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**